Singapore, Dec 27, 2011: Australia-based QRxPharma has announced the execution of a binding letter of intent (LOI) with Actavis for the formation of a strategic partnership to commercialise MoxDuo IR in the US acute pain marketplace.

MoxDuo IR is a patented 3:2 ratio fixed dose combination of morphine and oxycodone. Actavis is a subsidiary of Actavis Group, a privately held company based in Europe with 10,000 employees and annual global sales in excess of EUR 1.8 billion. Actavis Group is the world’s fourth largest generic pharmaceutical company with a growing franchise in branded products.

The launch of MoxDuo IR in the US is projected to occur in 3Q CY2012, and pre-launch preparations will begin immediately.